Ulf H Dolling

6407255, Jun 18, 2002

Sep 10, 2001

09/950286

Ian Frank Cottrell - Hertford, GB
Ulf H Dolling - Westfield NJ
David Hands - London, GB
Robert Darrin Wilson - London, GB

Merck Sharp Dohme Ltd. - Hoddesdon

C07D24912

5482632

The present invention relates to a process for the preparation of morpholine derivatives of formula (I) which are useful as a therapeutic agents.

7022841, Apr 4, 2006

Sep 20, 2002

10/485134

Raymond Cvetovich - Scotch Plains NJ, US
Robert Wenslow - East Windsor NJ, US
John M. Williams - Belle Mead NJ, US
Daniel Sidler - Whitehouse Station NJ, US
Louis Crocker - Belle Mead NJ, US
Hsien-Hsin Tung - Edison NJ, US
Brian K. Johnson - Princeton NJ, US
Joseph Kukura, II - Somerset NJ, US
Ulf Dolling - Westfield NJ, US

Merck & Co. Inc. - Rahway NJ

C07D 477/20

540350, 540320, 540351

The present invention relates to a process for reducing the levels of organic solvents to pharmaceutically acceptable levels in thermally unstable crystalline carbapenem solids represented by formula I: or a salt thereof, wherein Rand R, are the same or different, and are selected from H, alkyl, aryl, and heteroaryl, comprising washing a carbapenem solid containing organic solvent with an organic solvent containing water; and using vacuum and/or inert gas (hydrated or dry) at low temperature to produce a compound of formula I containing pharmaceutically acceptable levels of organic solvents, wherein the water content of the crystalline carbapenem solid, correcting for organic solvents, is maintained at about 13% to about 25% during the process.

7411088, Aug 12, 2008

Feb 16, 2005

10/589098

Karel Marie Joseph Brands - London, GB
Sarah Elizabeth Brewer - Biggleswade, GB
Antony John Davies - Princeton NJ, US
Ulf H. Dolling - Westfield NJ, US
Deborah Camille Hammond - Rickmansworth, GB
David Ross Lieberman - London, GB
Jeremy Peter Scott - Hertford, GB

Merck & Co., Inc. - Rahway NJ
Merck Sharp & Dohme Ltd. - Hoddesdon, Hertfordshire

C07C 315/00

562429, 568 31

There is provided stereoselective route to a compound of formula I:.

7598264, Oct 6, 2009

Mar 9, 2005

10/587682

Wei Han - West Chester PA, US
Melissa Egbertson - Ambler PA, US
John S. Wai - Harleysville PA, US
Linghang Zhuang - Chalfont PA, US
Rowena D. Ruzek - North Wales PA, US
Debra S. Perlow - East Greenville PA, US
Mark Cameron - Brick NJ, US
Bruce S. Foster - Scoth Plains NJ, US
Ulf H. Dolling - Westfield NJ, US
R. Scott Hoerrner - Westfield NJ, US
Philip J. Pye - Guttenberg NJ, US
Remy Angelaud - Union NJ, US
Danny E. Mancheno - Rego Park NY, US
David Askin - Warren NJ, US

Merck & Co., Inc. - Rahway NJ

A01N 43/42
A61K 31/44
C07D 471/02
C07D 491/02
C07D 498/02
C07D 513/02

514300, 546113

Hydroxy (tetra- or hexa-)hydronaphthyridine dione compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I) wherein a, R1?, R2?, R3?, R4? and R5? are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

20020103379, Aug 1, 2002

Dec 6, 2001

10/013063

Ulf Dolling - Westfield NJ, US
Ramon Alabaster - Puckeridge, GB
Michael Ashwood - Bishops Stortford, GB
Ian Cottrell - Hertford, GB
Cameron Cowden - Stanstead Abbotts, GB
Antony Davies - Hertford, GB
David Hands - London, GB
Debra Wallace - Stanstead Abbotts, GB
Robert Wilson - London, GB

C07D213/28

546/339000

The invention is a process for preparing 3-fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide which comprises coupling with 2-aminomethyl-3-fluoropyridine dihydrochloric acid salt in the presence of a coupling reagent and a base to form 3-fluoro-2-pyridylmethyl-3-(2,2-difluoro-2-(2-pyridyl)ethylamino)-6-chloropyrazin-2-one-1-acetamide.

45785090, Mar 25, 1986

Feb 17, 1984

6/579341

Ulf H. Dolling - Westfield NJ
Seemon H. Pines - Murray Hill NJ
Edward J. J. Grabowski - Westfield NJ

Merck & Co., Inc. - Rahway NJ

C07C 4561
C07C 5990

562462

A process is disclosed for obtaining manipulated proportions of the (+) and (-) enantiomers of [(6,7-dichloro-2,3-dihydro-2-methyl-1-oxo-2-phenyl-1H-inden-5-yl)oxy]aceti c acid by asymmetric chiral phase transfer catalysis.

50934988, Mar 3, 1992

Jun 28, 1991

7/724415

Ulf H. Dolling - Westfield NJ
Seemon H. Pines - Murray Hill NJ
Edward J. J. Grabowski - Westfield NJ

Merck & Co., Inc. - Rahway NJ

C07D45304

546134

A process is disclosed for obtaining manipulated proportions of the (+) and (-) enantiomers of [(6,7-dichloro-2,3-dihydro-2-methyl-1-oxo-2-phenyl-1H-inden-5-yl)oxy]aceti c acid by asymmetric chiral phase transfer catalysis.

50618016, Oct 29, 1991

Sep 24, 1990

7/586922

John M. Williams - Somerset NJ
Ulf H. Dolling - Westfield NJ

Merck & Co., Inc. - Rahway NJ

C07J 7300
A61K 3158

546 77

Described is a new intermediate and new process for preparing 3-oxo-4-aza-androst-1-ene 17. beta. -ketones. The process involves converting the corresponding 17. beta. -alkyl carboxylate to the N-methoxy-N-methyl carboxamide and reacting this with an appropriate Grignard reagent to form the desired ketone. The reaction can be conducted in "one pot", thus eliminating isolation of intermediates and avoiding the use of less stable intermediates, e. g. , acid chlorides, acyl imidazolides and the like. The intermediate has the formula: ##STR1## wherein R. sup. 1 is hydrogen.